Boryung Corporation
Financials
Valuation Metrics
Boryung Corporation's Market Cap is ₩7120B. At end of 2025 it was ₩7729B. Ranked #379 of 2,421 in KR market (top 16%), #253 of 781 on KOSPI (top 32%), #42 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 18%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 712.03B KRW | KR#379/2,421 Sec#42/231 |
| Revenue | 1.06T KRW | KR#393/2,421 Sec#13/231 |
| Net Income | 120.58B KRW | KR#219/2,421 Sec#12/231 |
| Total Assets | 1.53T KRW | KR#370/2,421 Sec#17/231 |
| Net Assets | 894.81B KRW | KR#317/2,421 Sec#19/231 |
| Employees | 1,646 | KR#168/2,421 Sec#10/231 |
| Value | ||
| P/E | 5.90x | KR#445/2,421 Sec#17/231 |
| P/B | 0.80x | KR#1,258/2,421 Sec#76/231 |
| PEG | 0.02x | KR#185/2,421 Sec#7/231 |
| P/S | 0.67x | KR#1,117/2,421 Sec#53/231 |
| EV/EBITDA | 11.85x | KR#711/2,421 Sec#38/231 |
| FCF Yield | 15.58% | KR#426/2,421 Sec#11/231 |
| Profitability | ||
| ROE | 13.48% | KR#393/2,421 Sec#27/231 |
| ROA | 7.88% | KR#446/2,421 Sec#35/231 |
| Op. Margin | 6.86% | KR#741/2,421 Sec#59/231 |
| Revenue Growth | 3.95% | KR#1,267/2,421 Sec#130/231 |
| Earnings Growth | 279.18% | KR#182/2,421 Sec#10/231 |
| Financial Health | ||
| Debt Ratio | 71.04% | KR#1,234/2,421 Sec#149/231 |
| Total Debt | 199.67B KRW | KR#516/2,421 Sec#27/231 |
| FCF | 110.94B KRW | KR#184/2,421 Sec#10/231 |
| Cash | 50.04B KRW | KR#735/2,421 Sec#41/231 |
| Current Ratio | 1.71x | KR#1,027/2,421 Sec#116/231 |
| Net Debt/EBITDA | 2.06x | KR#839/2,421 Sec#61/231 |
| Dividend | ||
| Div. Yield | 1.94% | KR#892/2,421 Sec#45/231 |
| Div. Growth | 60.00% | KR#201/2,421 Sec#7/231 |
| Performance | ||
| 1Y Return | -4.05% | KR#815/2,421 Sec#50/231 |
| 1M Return | -7.68% | KR#1,984/2,421 Sec#163/231 |
| From 52W High | -23.15% | KR#337/2,421 Sec#16/231 |
| 1Y MDD | -29.12% | KR#222/2,421 Sec#14/231 |
| Trading | ||
| Volume | 92,049 shares | KR#822/2,421 Sec#76/231 |
| Trading Value | 774.4M KRW | KR#793/2,421 Sec#81/231 |
| Foreign Own. | 5.86% | KR#749/2,421 Sec#68/231 |
| Per Share | ||
| EPS | 1,406 KRW | KR#591/2,421 Sec#41/231 |
| BPS | 10,431 KRW | KR#964/2,421 Sec#67/231 |
Company Info
Boryung, established in 1963 and listed on the securities market in 1988, operates in pharmaceutical manufacturing and sales. The company is expanding its market share in chronic metabolic diseases and oncology with its new drug Kanarb in the professional pharmaceutical sector, achieving results across diverse business divisions. Boryung strives to become a leading healthcare company with high profitability and stable cash generation by maximizing proprietary product capabilities and expanding essential medicine manufacturing infrastructure. Boryung is headquartered in Jongno-gu, Seoul.